InVivo Therapeutics Holdings Corp (NVIVQ)

[The Lawman]

Reversion of two patients disappointing but not fatal.

If the scaffold is approved by the FDA in early 2018, as the company expects, NVIV will have only FDA approved device for treatment of SCI that has achieved positive results in a still much higher than typical percentage of the SCI population.

In addition, a clinical study for the much larger cervical SCI population has been approved, and will be soon starting, in Canada. If successful, that could greatly expand the use of the scaffold.

Down the road, the scaffold will be seeded with stem cells that should make it much more effective.

There will be blood on the streets of In Vivo tomorrow, which is the time for those with conviction and cojones to buy.

LM